Targeting ATRX Loss through Inhibition of the Cell-Cycle Checkpoint Mediator WEE1.
Cancer Res
; 80(3): 375-376, 2020 02 01.
Article
en En
| MEDLINE
| ID: mdl-32015155
ABSTRACT
In this issue of Cancer Research, Liang and colleagues perform a genome-wide CRISPR-Cas9-negative loss-of-function screen and identify WEE1 kinase as a therapeutic vulnerability in cells depleted of the ATRX chromatin remodeler gene. Because ATRX mutations are frequently mutated across a variety of pediatric and adult malignancies, this work may contribute to the preclinical rationale for a precision medicine trial of the WEE1 inhibitor AZD1775 (adavosertib) for patients whose tumors demonstrate ATRX loss.See related article by Liang et al., p. 510.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Proteínas Tirosina Quinasas
/
Neoplasias
Límite:
Adult
/
Child
/
Humans
Idioma:
En
Revista:
Cancer Res
Año:
2020
Tipo del documento:
Article